Literature DB >> 26195796

Huntington's disease: Neural dysfunction linked to inositol polyphosphate multikinase.

Ishrat Ahmed1, Juan I Sbodio1, Maged M Harraz1, Richa Tyagi1, Jonathan C Grima1, Lauren K Albacarys1, Maimon E Hubbi2, Risheng Xu1, Seyun Kim3, Bindu D Paul4, Solomon H Snyder5.   

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disease caused by a glutamine repeat expansion in mutant huntingtin (mHtt). Despite the known genetic cause of HD, the pathophysiology of this disease remains to be elucidated. Inositol polyphosphate multikinase (IPMK) is an enzyme that displays soluble inositol phosphate kinase activity, lipid kinase activity, and various noncatalytic interactions. We report a severe loss of IPMK in the striatum of HD patients and in several cellular and animal models of the disease. This depletion reflects mHtt-induced impairment of COUP-TF-interacting protein 2 (Ctip2), a striatal-enriched transcription factor for IPMK, as well as alterations in IPMK protein stability. IPMK overexpression reverses the metabolic activity deficit in a cell model of HD. IPMK depletion appears to mediate neural dysfunction, because intrastriatal delivery of IPMK abates the progression of motor abnormalities and rescues striatal pathology in transgenic murine models of HD.

Entities:  

Keywords:  Akt; Ctip2; Huntington's disease; IPMK; inositol polyphosphate multikinase

Mesh:

Substances:

Year:  2015        PMID: 26195796      PMCID: PMC4534278          DOI: 10.1073/pnas.1511810112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.

Authors:  Anthone W Dunah; Hyunkyung Jeong; April Griffin; Yong-Man Kim; David G Standaert; Steven M Hersch; M Maral Mouradian; Anne B Young; Naoko Tanese; Dimitri Krainc
Journal:  Science       Date:  2002-05-02       Impact factor: 47.728

Review 3.  Back in the water: the return of the inositol phosphates.

Authors:  R F Irvine; M J Schell
Journal:  Nat Rev Mol Cell Biol       Date:  2001-05       Impact factor: 94.444

4.  Synthesis of diphosphoinositol pentakisphosphate by a newly identified family of higher inositol polyphosphate kinases.

Authors:  A Saiardi; H Erdjument-Bromage; A M Snowman; P Tempst; S H Snyder
Journal:  Curr Biol       Date:  1999-11-18       Impact factor: 10.834

5.  Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice.

Authors:  Silvia Gines; Ihn Sik Seong; Elisa Fossale; Elena Ivanova; Flavia Trettel; James F Gusella; Vanessa C Wheeler; Francesca Persichetti; Marcy E MacDonald
Journal:  Hum Mol Genet       Date:  2003-03-01       Impact factor: 6.150

6.  A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control.

Authors:  A R Odom; A Stahlberg; S R Wente; J D York
Journal:  Science       Date:  2000-03-17       Impact factor: 47.728

7.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.

Authors:  J S Steffan; L Bodai; J Pallos; M Poelman; A McCampbell; B L Apostol; A Kazantsev; E Schmidt; Y Z Zhu; M Greenwald; R Kurokawa; D E Housman; G R Jackson; J L Marsh; L M Thompson
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

8.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt.

Authors:  Sandrine Humbert; Elzbieta A Bryson; Fabrice P Cordelières; Nathan C Connors; Sandeep R Datta; Steven Finkbeiner; Michael E Greenberg; Frédéric Saudou
Journal:  Dev Cell       Date:  2002-06       Impact factor: 12.270

9.  Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.

Authors:  C Zuccato; A Ciammola; D Rigamonti; B R Leavitt; D Goffredo; L Conti; M E MacDonald; R M Friedlander; V Silani; M R Hayden; T Timmusk; S Sipione; E Cattaneo
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

10.  Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells.

Authors:  F Trettel; D Rigamonti; P Hilditch-Maguire; V C Wheeler; A H Sharp; F Persichetti; E Cattaneo; M E MacDonald
Journal:  Hum Mol Genet       Date:  2000-11-22       Impact factor: 6.150

View more
  19 in total

1.  Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes.

Authors:  P Conforti; D Besusso; V D Bocchi; A Faedo; E Cesana; G Rossetti; V Ranzani; C N Svendsen; L M Thompson; M Toselli; G Biella; M Pagani; E Cattaneo
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

2.  Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease.

Authors:  Jennifer S Yokoyama; Yunpeng Wang; Andrew J Schork; Wesley K Thompson; Celeste M Karch; Carlos Cruchaga; Linda K McEvoy; Aree Witoelar; Chi-Hua Chen; Dominic Holland; James B Brewer; Andre Franke; William P Dillon; David M Wilson; Pratik Mukherjee; Christopher P Hess; Zachary Miller; Luke W Bonham; Jeffrey Shen; Gil D Rabinovici; Howard J Rosen; Bruce L Miller; Bradley T Hyman; Gerard D Schellenberg; Tom H Karlsen; Ole A Andreassen; Anders M Dale; Rahul S Desikan
Journal:  JAMA Neurol       Date:  2016-06-01       Impact factor: 18.302

Review 3.  Structural analyses of inositol phosphate second messengers bound to signaling effector proteins.

Authors:  Raymond D Blind
Journal:  Adv Biol Regul       Date:  2019-10-11

4.  Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism.

Authors:  Aloysius Domingo; David Amar; Karen Grütz; Lillian V Lee; Raymond Rosales; Norbert Brüggemann; Roland Dominic Jamora; Eva Cutiongco-Dela Paz; Arndt Rolfs; Dirk Dressler; Uwe Walter; Dimitri Krainc; Katja Lohmann; Ron Shamir; Christine Klein; Ana Westenberger
Journal:  Cell Mol Life Sci       Date:  2016-02-15       Impact factor: 9.261

Review 5.  Inositol polyphosphate multikinase (IPMK) in transcriptional regulation and nuclear inositide metabolism.

Authors:  M Merced Malabanan; Raymond D Blind
Journal:  Biochem Soc Trans       Date:  2016-02       Impact factor: 5.407

Review 6.  The Inositol Phosphate System-A Coordinator of Metabolic Adaptability.

Authors:  Becky Tu-Sekine; Sangwon F Kim
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

7.  Structural features of human inositol phosphate multikinase rationalize its inositol phosphate kinase and phosphoinositide 3-kinase activities.

Authors:  Huanchen Wang; Stephen B Shears
Journal:  J Biol Chem       Date:  2017-09-07       Impact factor: 5.157

Review 8.  Inositol Polyphosphate Multikinase Signaling: Multifaceted Functions in Health and Disease.

Authors:  Boah Lee; Seung Ju Park; Sehoon Hong; Kyunghan Kim; Seyun Kim
Journal:  Mol Cells       Date:  2021-04-30       Impact factor: 5.034

9.  Neuroprotective effect of caffeic acid phenethyl ester in 3-nitropropionic acid-induced striatal neurotoxicity.

Authors:  Jia Bak; Hee Jung Kim; Seong Yun Kim; Yun-Sik Choi
Journal:  Korean J Physiol Pharmacol       Date:  2016-04-26       Impact factor: 2.016

Review 10.  Inositol polyphosphate-protein interactions: Implications for microbial pathogenicity.

Authors:  Sophie Lev; Bethany Bowring; Desmarini Desmarini; Julianne Teresa Djordjevic
Journal:  Cell Microbiol       Date:  2021-03-25       Impact factor: 4.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.